A study to find how well VES001 works and how safe it is in participants with GRN -frontotemporal dementia (GRN-FTD) showing no symptoms

2024-513258-31-00 Protocol FTD002 Human pharmacology (Phase I) - Other Ended

Start 11 Dec 2024 · End 5 Aug 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol FTD002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 6
Countries 1
Sites 1

Frontotemporal dementia (FTD)

Key facts

Sponsor
Vesper Bio ApS, Vesper Bio ApS
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10], Phenomena and Processes [G] - Genetic Phenomena [G05]
Trial duration
11 Dec 2024 → 5 Aug 2025
Decision date (initial)
2024-10-28
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-513258-31-00
WHO UTN
U1111-1311-8366

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Frontotemporal dementia (FTD)

VersionLevelCodeTermSystem organ class
21.1 PT 10068968 Frontotemporal dementia 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Vesper Bio ApS

Sponsor organisation
Vesper Bio ApS
Address
Scherfigsvej 7
City
Copenhagen Oe
Postcode
2100
Country
Denmark

Scientific contact point

Organisation
Vesper Bio ApS
Contact name
Mads Kjolby

Public contact point

Organisation
Vesper Bio ApS
Contact name
Mads Kjolby

Vesper Bio ApS

Sponsor organisation
Vesper Bio ApS
Address
4th Floor, Hauser Plads 10 Hauser Plads 10
City
Copenhagen K
Postcode
1127
Country
Denmark

Scientific contact point

Organisation
Vesper Bio ApS
Contact name
Mads Kjolby

Public contact point

Organisation
Vesper Bio ApS
Contact name
Mads Kjolby

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 3 1
Rest of world
United Kingdom
3

Investigational sites

Netherlands

1 site · Ended
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neurologie, Dr. Molewaterplein 40, 3015 GD, Rotterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-12-11 2025-07-08 2025-02-17 2025-02-25

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-26 Netherlands Acceptable
2024-10-28
2024-10-28
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-27 Netherlands Acceptable
2024-12-13
2024-12-16
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-21 Netherlands Acceptable
2024-12-13
2025-02-21
4 NON SUBSTANTIAL MODIFICATION NSM-2 2025-02-25 Netherlands Acceptable
2024-12-13
2025-02-25
5 SUBSTANTIAL MODIFICATION SM-3 2025-03-04 Netherlands Acceptable
2025-03-28
2025-04-01